Shares of Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.03, with a volume of 839,780 shares trading hands.
Mateon Therapeutics Stock Up 6.1 %
The stock’s 50 day moving average is $0.04 and its two-hundred day moving average is $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Read More
- Five stocks we like better than Mateon Therapeutics
- What does consumer price index measure?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Buy P&G Now, Before It Sets A New All-Time High
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Basic Materials Stocks Investing
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
